Amgen receives EC approval for Uplizna in generalised myasthenia gravis

​Amgen has secured EC approval for Uplizna as an add-on treatment to standard therapy for adults with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

The post Amgen receives EC approval for Uplizna in generalised myasthenia gravis appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Medtronic secures FDA approval for Stealth AXiS spine robotics platform
Immunic secures $400m fund to support commercial-stage development
Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us